Edition:
United States

Brainstorm Cell Therapuetics Inc (BCLI.OQ)

BCLI.OQ on NASDAQ Stock Exchange Capital Market

4.41USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$4.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
22,889
52-wk High
$5.34
52-wk Low
$2.88

Latest Key Developments (Source: Significant Developments)

BrainStorm Cell Therapuetics Reports Q1 Loss Per Share Of $0.12
Monday, 14 May 2018 08:00am EDT 

May 14 (Reuters) - Brainstorm Cell Therapuetics Inc ::BRAINSTORM ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE AND CLINICAL HIGHLIGHTS.Q1 LOSS PER SHARE $0.12.  Full Article

Brainstorm Cell Received Good Manufacturing Practice Approval From Israel Ministry Of Health
Thursday, 4 Jan 2018 09:45am EST 

Jan 4 (Reuters) - Brainstorm Cell Therapuetics Inc ::BRAINSTORM CELL THERAPUETICS - RECEIVED GOOD MANUFACTURING PRACTICE APPROVAL FROM ISRAEL MINISTRY OF HEALTH FOR ISRAELI CONTRACT MANUFACTURING FACILITY.BRAINSTORM CELL THERAPUETICS INC - APPROVAL ADVANCES CO'S APPLICATION TO ISRAEL MOH FOR TREATMENT OF ALS PATIENTS IN ISRAEL FOR A FEE.  Full Article

Brainstorm Cell Therapuetics names Eyal Rubin CFO
Thursday, 2 Nov 2017 09:03am EDT 

Nov 2 (Reuters) - Brainstorm Cell Therapuetics Inc :Brainstorm strengthens executive team: appoints Eyal Rubin as chief financial officer.Eyal Rubin joins co from Teva Pharmaceutical Industries Ltd.  Full Article

Brainstorm reports Q3 loss per share of $0.13
Tuesday, 17 Oct 2017 07:00am EDT 

Oct 17 (Reuters) - Brainstorm Cell Therapuetics Inc :Brainstorm announces third quarter 2017 financial results.Q3 loss per share $0.13.  Full Article

Brainstorm reports Q2 loss per share of $0.06
Tuesday, 15 Aug 2017 01:00am EDT 

Aug 15 (Reuters) - Brainstorm Cell Therapuetics Inc -:Brainstorm announces second quarter 2017 financial results.Q2 loss per share $0.06.  Full Article

BrainStorm Cell Therapuetics Q2 loss per share $0.06
Monday, 14 Aug 2017 04:30pm EDT 

Aug 14 (Reuters) - Brainstorm Cell Therapuetics Inc :BrainStorm announces second quarter 2017 financial results.Q2 loss per share $0.06.  Full Article

Brainstorm announces agreement with University of California Irvine Medical Center
Tuesday, 25 Jul 2017 07:00am EDT 

July 25 (Reuters) - Brainstorm Cell Therapuetics Inc :Brainstorm announces agreement with university of california irvine medical center to participate in phase 3 trial of nurown® in als.  Full Article

BrainStorm Cell Therapuetics Q1 loss per share $0.10
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - BrainStorm Cell Therapuetics Inc :BrainStorm announces first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.10.  Full Article

Brainstorm Cell Therapuetics Q4 loss per share $0.03
Thursday, 30 Mar 2017 12:30am EDT 

Brainstorm Cell Therapuetics Inc : Brainstorm announces financial results for 2016 and provides business update .Q4 loss per share $0.03.  Full Article

Brainstorm Cell Therapuetics signs MoU with Tel Aviv Sourasky Medical Center
Wednesday, 1 Mar 2017 06:45am EST 

Brainstorm Cell Therapuetics Inc : Brainstorm Cell Therapuetics-signed MOU with medical research, infrastructure, and health services fund of Tel Aviv Sourasky Medical Center . Brainstorm Cell Therapuetics Inc- agreement is expected to be formalized in first half of 2017 . Brainstorm Cell Therapuetics - MOU also covers participation of Tel Aviv Sourasky Medical Center in planned phase 3 trial that will investigate nurown in ALS . Brainstorm Cell- MOU to explore possibility of making nurown available to als patients under provisions of hospital exemption regulation . Brainstorm cell - mou sets forth terms under which co, tel aviv sourasky medical center would work to submit application to israeli ministry of health .Brainstorm cell therapuetics - signed mou to explore possibility of making nurown available to als patients under hospital exemption regulation.  Full Article

BRIEF-BrainStorm Cell Therapuetics Reports Q1 Loss Per Share Of $0.12

* BRAINSTORM ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE AND CLINICAL HIGHLIGHTS